Cargando…

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)

Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment optio...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, Susanne, Schubert, Maria-Luisa, Wang, Lei, He, Bailin, Neuber, Brigitte, Dreger, Peter, Müller-Tidow, Carsten, Schmitt, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406805/
https://www.ncbi.nlm.nih.gov/pubmed/30736352
http://dx.doi.org/10.3390/jcm8020200
_version_ 1783401408342523904
author Hofmann, Susanne
Schubert, Maria-Luisa
Wang, Lei
He, Bailin
Neuber, Brigitte
Dreger, Peter
Müller-Tidow, Carsten
Schmitt, Michael
author_facet Hofmann, Susanne
Schubert, Maria-Luisa
Wang, Lei
He, Bailin
Neuber, Brigitte
Dreger, Peter
Müller-Tidow, Carsten
Schmitt, Michael
author_sort Hofmann, Susanne
collection PubMed
description Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly desirable. This article gives an overview on the state-of-the art of preclinical and clinical studies on suitable target antigens for CAR T cell therapy in AML patients.
format Online
Article
Text
id pubmed-6406805
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64068052019-03-22 Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) Hofmann, Susanne Schubert, Maria-Luisa Wang, Lei He, Bailin Neuber, Brigitte Dreger, Peter Müller-Tidow, Carsten Schmitt, Michael J Clin Med Review Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly desirable. This article gives an overview on the state-of-the art of preclinical and clinical studies on suitable target antigens for CAR T cell therapy in AML patients. MDPI 2019-02-06 /pmc/articles/PMC6406805/ /pubmed/30736352 http://dx.doi.org/10.3390/jcm8020200 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hofmann, Susanne
Schubert, Maria-Luisa
Wang, Lei
He, Bailin
Neuber, Brigitte
Dreger, Peter
Müller-Tidow, Carsten
Schmitt, Michael
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
title Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
title_full Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
title_fullStr Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
title_full_unstemmed Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
title_short Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
title_sort chimeric antigen receptor (car) t cell therapy in acute myeloid leukemia (aml)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406805/
https://www.ncbi.nlm.nih.gov/pubmed/30736352
http://dx.doi.org/10.3390/jcm8020200
work_keys_str_mv AT hofmannsusanne chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml
AT schubertmarialuisa chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml
AT wanglei chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml
AT hebailin chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml
AT neuberbrigitte chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml
AT dregerpeter chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml
AT mullertidowcarsten chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml
AT schmittmichael chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml